Methotrexate in psoriasis and psoriatic arthritis

Laura C. Coates; Joseph F. Merola; Suzanne M. Grieb; Philip J. Mease; Kristina Callis Duffin

doi:10.3899/jrheum.200124

Methotrexate in psoriasis and psoriatic arthritis

Laura C. Coates, Joseph F. Merola, Suzanne M. Grieb, Philip J. Mease, Kristina Callis Duffin

School of Medicine

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Methotrexate (MTX) is the most commonly prescribed first-line therapy in psoriatic arthritis (PsA) internationally and is also commonly used in the treatment of psoriasis. However, data supporting its use in PsA are limited and significant toxicities can occur. This article summarizes a debate at the 2019 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) annual meeting that focused on the use of MTX in psoriasis and PsA. Four clinicians and 1 patient research partner presented clinical study data and the patient experience summarizing the efficacy, tolerability, and toxicity of MTX for both skin and musculoskeletal manifestations. A survey of attending GRAPPA members collected data on current and planned future use of MTX across the world.

Original language	English (US)
Pages (from-to)	31-35
Number of pages	5
Journal	Journal of Rheumatology
Volume	96
DOIs	https://doi.org/10.3899/jrheum.200124
State	Published - Jun 1 2020

Keywords

Grappa
Methotrexate
Patient research partners
Psoriasis
Psoriatic arthritis

ASJC Scopus subject areas

Rheumatology
Immunology and Allergy
Immunology

Access to Document

10.3899/jrheum.200124

Cite this

@article{b7356154e83a4eecb4917faec23fa60e,

title = "Methotrexate in psoriasis and psoriatic arthritis",

abstract = "Methotrexate (MTX) is the most commonly prescribed first-line therapy in psoriatic arthritis (PsA) internationally and is also commonly used in the treatment of psoriasis. However, data supporting its use in PsA are limited and significant toxicities can occur. This article summarizes a debate at the 2019 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) annual meeting that focused on the use of MTX in psoriasis and PsA. Four clinicians and 1 patient research partner presented clinical study data and the patient experience summarizing the efficacy, tolerability, and toxicity of MTX for both skin and musculoskeletal manifestations. A survey of attending GRAPPA members collected data on current and planned future use of MTX across the world.",

keywords = "Grappa, Methotrexate, Patient research partners, Psoriasis, Psoriatic arthritis",

author = "Coates, {Laura C.} and Merola, {Joseph F.} and Grieb, {Suzanne M.} and Mease, {Philip J.} and Duffin, {Kristina Callis}",

year = "2020",

month = jun,

day = "1",

doi = "10.3899/jrheum.200124",

language = "English (US)",

volume = "96",

pages = "31--35",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

}

TY - JOUR

T1 - Methotrexate in psoriasis and psoriatic arthritis

AU - Coates, Laura C.

AU - Merola, Joseph F.

AU - Grieb, Suzanne M.

AU - Mease, Philip J.

AU - Duffin, Kristina Callis

PY - 2020/6/1

Y1 - 2020/6/1

N2 - Methotrexate (MTX) is the most commonly prescribed first-line therapy in psoriatic arthritis (PsA) internationally and is also commonly used in the treatment of psoriasis. However, data supporting its use in PsA are limited and significant toxicities can occur. This article summarizes a debate at the 2019 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) annual meeting that focused on the use of MTX in psoriasis and PsA. Four clinicians and 1 patient research partner presented clinical study data and the patient experience summarizing the efficacy, tolerability, and toxicity of MTX for both skin and musculoskeletal manifestations. A survey of attending GRAPPA members collected data on current and planned future use of MTX across the world.

AB - Methotrexate (MTX) is the most commonly prescribed first-line therapy in psoriatic arthritis (PsA) internationally and is also commonly used in the treatment of psoriasis. However, data supporting its use in PsA are limited and significant toxicities can occur. This article summarizes a debate at the 2019 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) annual meeting that focused on the use of MTX in psoriasis and PsA. Four clinicians and 1 patient research partner presented clinical study data and the patient experience summarizing the efficacy, tolerability, and toxicity of MTX for both skin and musculoskeletal manifestations. A survey of attending GRAPPA members collected data on current and planned future use of MTX across the world.

KW - Grappa

KW - Methotrexate

KW - Patient research partners

KW - Psoriasis

KW - Psoriatic arthritis

UR - http://www.scopus.com/inward/record.url?scp=85085909787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085909787&partnerID=8YFLogxK

U2 - 10.3899/jrheum.200124

DO - 10.3899/jrheum.200124

M3 - Article

C2 - 32482765

AN - SCOPUS:85085909787

SN - 0315-162X

VL - 96

SP - 31

EP - 35

JO - Journal of Rheumatology

JF - Journal of Rheumatology

ER -

Methotrexate in psoriasis and psoriatic arthritis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this